| 29.655 -0.215 (-0.72%) | 11-18 13:51 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 38.04 |
1-year : | 44.81 |
| Resists | First : | 32.57 |
Second : | 38.36 |
| Pivot price | 28.77 |
|||
| Supports | First : | 23.19 | Second : | 19.29 |
| MAs | MA(5) : | 27.94 |
MA(20) : | 30.14 |
| MA(100) : | 39.54 |
MA(250) : | 29.99 |
|
| MACD | MACD : | -2.6 |
Signal : | -3 |
| %K %D | K(14,3) : | 49.8 |
D(3) : | 37.9 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 50.81 | Low : | 16.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ URGN ] has closed below upper band by 46.8%. Bollinger Bands are 60.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 29.94 - 30.05 | 30.05 - 30.14 |
| Low: | 26.8 - 26.93 | 26.93 - 27.04 |
| Close: | 29.66 - 29.88 | 29.88 - 30.05 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Sat, 14 Nov 2026
A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $58 to $75 - Moomoo
Sat, 14 Nov 2026
UroGen Pharma Ltd. (URGN) stock price, news, quote and history - Yahoo Finance UK
Wed, 04 Nov 2026
UroGen Pharma Ltd. (URGN) Q3 FY2026 earnings call transcript - Yahoo Finance
Wed, 04 Nov 2026
UroGen Pharma Ltd (URGN) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Wed, 28 Oct 2026
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60 - 富途牛牛
Tue, 13 Oct 2026
UroGen Pharma: An Emerging GARP Stock - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 98.1 (%) |
| Shares Short | 5,610 (K) |
| Shares Short P.Month | 6,250 (K) |
| EPS | -1.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.55 |
| Profit Margin | -26.3 % |
| Operating Margin | 9.3 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 223.8 % |
| Gross Profit (p.s.) | 4.66 |
| Sales Per Share | 5.1 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -22.3 |
| PEG Ratio | 0 |
| Price to Book value | -11.46 |
| Price to Sales | 5.72 |
| Price to Cash Flow | -10.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |